Division of Translational Research, Tata Memorial Centre, ACTREC, Navi, Mumbai, India.
J Drug Target. 2013 Feb;21(2):126-36. doi: 10.3109/1061186X.2012.731069. Epub 2012 Oct 15.
Gastrointestinal (GI) malignancies are one of the most frequently occurring tumors found worldwide. Surgery remains the primary treatment for most solid tumors and adjuvant chemotherapy and radiotherapy are limited by lack of specificity and toxicity. In view of the poor survival rate, there is a great need to introduce new and effective therapeutic modalities. Recently, dendritic cells (DCs)-based vaccines are being explored as a promising therapeutic strategy but their success is limited by the tumor-induced immune escape mechanisms. This article provides a comprehensive analysis of clinical trials conducted using this approach. It also showcases the necessity of exploring nano-engineered strategies for improving the clinical utility of DC-vaccination for GI tract malignancies to overcome immune tolerance.
胃肠道（GI）恶性肿瘤是全球最常见的肿瘤之一。手术仍然是大多数实体瘤的主要治疗方法，而辅助化疗和放疗因缺乏特异性和毒性而受到限制。鉴于存活率低，非常有必要引入新的有效治疗方式。最近，基于树突状细胞（DC）的疫苗作为一种很有前途的治疗策略正在被探索，但由于肿瘤诱导的免疫逃逸机制，其成功受到限制。本文全面分析了使用这种方法进行的临床试验。还展示了探索纳米工程策略的必要性，以提高用于胃肠道恶性肿瘤的 DC 疫苗的临床实用性，从而克服免疫耐受。
